Drugs and patents in ATC class R03DX - Other systemic drugs for obstructive airway diseases

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
APHTHASOL	amlexanox
AMLEXANOX	amlexanox
ZORYVE	roflumilast
DALIRESP	roflumilast
ROFLUMILAST	roflumilast
>Tradename	>Generic Name

Last updated: June 7, 2026

Executive summary: ATC R03DX (“Other systemic drugs for obstructive airway diseases”) is a catch-all category with heterogeneous pharmacologies and uneven FDA footprint. Patent coverage is dominated by (1) originator small molecules with late-stage lifecycle management, (2) biologic-adjacent assets in rare “other” segments where applicable, and (3) method-of-use and dosing regimens rather than core compound protection for many marketed products. For new entrants, generic entry risk is driven more by Orange Book breadth (formulation, salt, polymorph, and method-of-use listings) and by litigation history (including Paragraph IV outcomes) than by primary patent term. Commercial dynamics are shaped by guideline positioning, payer reimbursement constraints, and step-therapy controls that limit “systemic other” uptake despite chronic disease prevalence.

What drugs sit inside ATC R03DX, and how does the category drive patent risk?

Featured snippet answer: R03DX is an ATC bucket for “other systemic” therapies in obstructive airway diseases, so patent risk varies by molecular class because the category mixes unrelated mechanisms rather than one platform.

How R03DX category composition affects IP estates

R03DX is used for cross-company, cross-mechanism aggregation. That creates three practical patent-analysis outcomes:

Estate dispersion: Each originator has distinct primary patent coverage, salt selection, and lifecycle management.
Different Orange Book inclusion patterns: Some systemic “other” products show long Orange Book listing tails; others have minimal secondary listings, lowering generic barriers.
Regulatory comparability differences: If the product relies on complex dosing algorithms or specific patient subsets, method-of-use patents can raise litigation and 505(b)(2) risk even when chemistry-to-compare looks straightforward.

Common product archetypes analysts treat as R03DX exposure

Even without a one-to-one mapping to FDA products, R03DX activity typically clusters into:

Small-molecule add-ons used when inhaled regimens are insufficient or not tolerated.
Systemic anti-inflammatory or immunomodulatory compounds where the label supports constrained use cases.
Anticholinergic or bronchodilator systemic agents (older actives more likely, where “other” persists).
Other systemic agents that do not fit into R03A (beta2 agonists), R03B (other inhaled adrenergics), R03C (inhaled anticholinergics), or R03D (other inhaled drugs).

Because the category is heterogeneous, the patent landscape is best evaluated by product-by-product originator estates rather than by ATC alone.

Which patents protect “other systemic” obstructive airway drugs in R03DX?

Featured snippet answer: Protection typically spans compound or salt claims (primary), plus secondary claims on crystalline form, composition, dosing regimen, and method-of-use for specific obstructive airway indications.

Patent estate structure that most often blocks generic substitution

Across systemic “other” obstructive airway therapies, the blocking layers usually map to:

Active ingredient patents (compound and/or salt).
Polymorph/crystal form and solid-state patents (especially if the marketed form is locked to a specific structure).
Composition and formulation patents (e.g., matrix, coating, release profile).
Method-of-use and patient-selection patents (lines of therapy, severity stratification, corticosteroid-sparing use, or combination use).
Manufacturing process patents (less common for successful generic entry, but relevant for 505(b)(2) and authorized generics).

Lifecycle management patterns that extend effective exclusivity

For systemic products used chronically, originators often extend:

New dosing strengths or regimens (unit dose or frequency).
New combinations (including add-on therapy).
Crystalline form switching to improve bioavailability or stability, then filing follow-on patents tied to the new form.

These patterns increase the number of Orange Book “listed patents” even where the core compound is older.

When do key R03DX assets lose exclusivity, and what triggers generic launch?

Featured snippet answer: Generic launch timing is driven by the latest of (a) patent expiry for listed patents that block marketing, (b) any statutory exclusivity (3, 5, 7 years depending on FDA approval history), and (c) the resolution date of litigation tied to Paragraph IV filings.

Exclusivity timeline mechanics (what matters in R03DX)

For “other systemic” obstructive airway drugs, generic entry commonly waits for:

Primary patent expiry on compound/salt.
Secondary patent expiry on method-of-use or solid state.
BLA/Biologics not typical for R03DX, but where present, biologic exclusivities can supersede typical small-molecule timelines.

Launch triggers analysts track

Orange Book “listed patent” expiration dates per NDA.
Court outcomes for Paragraph IV.
Settlement terms (carve-outs by strength, formulation, or labeling).
Authorized generic timing post-settlement, which can compress market entry windows.

What patent expirations and Orange Book listings determine generic entry risks for R03DX?

Featured snippet answer: Orange Book breadth is the most predictive variable for generic entry resistance in R03DX because secondary listings (method-of-use, dosing regimen, solid state) can delay marketing even after compound expiry.

How to interpret Orange Book listing density

High listing density generally indicates:

Method-of-use coverage that tracks label text.
Multiple crystalline forms or salts.
Strength-by-strength patenting.

Low listing density indicates:

Earlier stripping of lifecycle claims.
Fewer “easy design-around” routes for generics, depending on formulation dependence.

Are Paragraph IV challenges common for ATC R03DX systemic obstructive airway drugs?

Featured snippet answer: Paragraph IV activity is common when Orange Book lists multiple blocking patents that expire at different times, but it is highly product-specific in R03DX due to the category’s heterogeneity.

What makes a Paragraph IV strategy succeed in this category

Narrow method-of-use claim scope tied to label language that can be changed through carve-outs.
Design-around for solid state (polymorph/crystal form) without changing active substance identity.
Early patent expiry windows that justify the risk and cost.

What makes Paragraph IV challenges likely to stall

Broad method-of-use claims that are hard to carve out without label redesign.
Manufacturing process or formulation claims with limited generic flexibility.
Settlement agreements that extend the effective launch date via exclusivity-like pay-for-delay structures.

What formulations and delivery system patents are protected for systemic “other” airway drugs?

Featured snippet answer: Systemic formulation protection often targets stability and solid-state properties, with polymorph and composition patents creating a barrier to simple generic replication.

Key formulation-IP hotspots

Polymorph/crystal form: the marketed form’s structure can be the anchor for multiple follow-on patents.
Salt selection: different salts can change solubility and are frequently patented.
Excipients and coatings: less dominant than solid-state, but still relevant when tied to release or bioavailability.
Dose-strength dependence: patents can be filed per strength to complicate partial generic entry.

What method-of-use patents protect R03DX indications, and how do they affect labeling carve-outs?

Featured snippet answer: Method-of-use patents often protect specific patient subsets, severity levels, and combination or step-therapy positioning, which can force generics into labeling carve-outs or trigger litigation.

Typical method-of-use claim scopes in obstructive airway systemic therapies

Common claim themes include:

Use in specific disease severity categories.
Use as adjunct therapy when inhaled options fail.
Corticosteroid-sparing or steroid reduction strategies.
Combination use with inhaled bronchodilators or inhaled anti-inflammatories.

How generic labels are shaped

Generics often pursue:

Narrower indications aligned to non-infringing method-of-use positions.
Label carve-outs that explicitly exclude the patented usage.
Papering changes via 505(b)(2) or narrower NDA labeling to avoid infringement.

Which companies own the R03DX patent estates, and who is challenging them?

Featured snippet answer: Company ownership is product-specific; R03DX estates usually map to the originator NDA holder and its assignees for solid-state and method-of-use patents, while challengers are typically large generics plus select 505(b)(2) specialists.

Competition pattern that appears in systemic “other” airway drugs

Originators defend with a mix of Orange Book strategy and litigation.
Generic challengers use Paragraph IV to secure early-to-market positions.
Authorized generics often appear post-settlement.

Because R03DX does not map cleanly to a single drug list, identifying exact holders and challengers requires product-level resolution to NDA/Orange Book entries.

What FDA status and Orange Book listings apply to R03DX systemic drugs?

Featured snippet answer: FDA status drives the enforceable IP set through Orange Book “listed patents,” which defines the patent hook for generic litigation and settlement scope.

Regulatory and IP linkage analysts rely on

NDA vs 505(b)(2): 505(b)(2) can use listed-patent referencing differently, but Orange Book still controls FDA approval-to-market timelines.
Patent listing on formulation vs active: if the listed patent covers a composition claim, generic design-around must avoid the patented composition while still meeting bioequivalence standards.

How does R03DX compare with other ATC obstructive airway categories for patent density and generic timing?

Featured snippet answer: Inhaled categories often have more device/formulation patents tied to inhalation performance, while R03DX systemic “other” categories more frequently rely on method-of-use and solid-state patents that can persist after compound expiry.

Practical comparison framework

Inhaled R03D (other inhaled drugs): device and formulation lock-in can be high.
R03DX systemic “other”: label positioning and solid-state can dominate.
Generic timing: R03DX often has fewer entrants early because of method-of-use carve-out complexity, even when primary compound expiry is earlier.

What patent litigation and settlements shape the R03DX generic landscape?

Featured snippet answer: Litigation and settlements determine the effective launch date, with settlement carve-outs often tied to strength, labeling, or formulation form.

What to look for in R03DX litigation posture

Who files Paragraph IV (challenger identity and strategy).
Which patents are asserted (method-of-use vs solid-state vs compound).
Settlement structure (date-based entry vs design-around with labeling carve-out).
Subsequent authorized generic (impacts revenue even if a settlement delays competition).

What generic entry risks exist for systemic “other” obstructive airway drugs?

Featured snippet answer: The highest generic entry risks come from:

multiple blocking patents listed across different expiration dates,
difficult method-of-use carve-outs,
and solid-state/formulation dependence that limits design-around options.

Risk matrix used for go/no-go decisions

Low risk: single primary patent expiry; minimal Orange Book tail; no method-of-use listings.
Medium risk: multiple secondary patents but narrow solid-state scope; possible label carve-outs.
High risk: broad method-of-use + multiple solid-state/formulation listings with active litigation and prior settlements.

Key takeaways for investors, BD teams, and litigation planners

R03DX is heterogeneous. Patent strength and launch timelines are product-specific, but the blocking mechanisms usually cluster in solid-state/formulation and method-of-use claims.
Orange Book listing breadth is the best proxy for generic resistance in “other systemic” obstructive airway drugs.
Generic timing is driven by the last blocking listed patent plus litigation/settlement outcomes, not by primary compound expiry alone.
BD and litigation strategies should prioritize mapping each listed patent to claim scope, label language, and realistic design-around pathways.

FAQs

How do I map ATC R03DX to enforceable US patents quickly?

Use product-level mapping from the NDA label and Orange Book listings, then anchor the patent set on the listed patents tied to the specific NDA (including method-of-use and solid-state entries).

What patent types most often survive to block generic entry in obstructive airway systemic drugs?

Method-of-use, dosing regimen, and solid-state (polymorph/salt) patents that align closely to label text and marketed drug form.

Do settlements in this category usually allow partial launch by strength or labeling?

Often. Settlements commonly include date-based entry and label carve-outs that limit infringement exposure and reduce immediate competitive overlap.

Are 505(b)(2) pathways a common alternative to generic 505(j) in R03DX?

They appear when design-around is difficult or when referencing changes can justify a narrower label. Whether it bypasses listed-patent constraints depends on Orange Book patent coverage and FDA pathway fit.

What commercialization factor matters most after patent expiry for R03DX systemic products?

Payer positioning and step-therapy constraints that affect uptake, even when IP barriers fall.

References

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
European Medicines Agency. ATC/DDD Index. https://www.whocc.no/atc_ddd_index/